deCODE Homepage - www.decode.com deCODE's Therapeutic Pipeline From Genes to Drugs About deCODE genetics Investors - DCGN deCODE services



These deCODE press releases were accurate at the time of their issuance. However, deCODE assumes no obligation to update, correct or otherwise modify any of these press releases.
Reykjavik, Iceland, November 22, 2006
deCODE genetics to Webcast Presentations at Lazard and Piper Jaffray Healthcare Conferences
Reykjavik, Iceland, November 17, 2006
deCODE Completes Senior Convertible Notes Offering

Reykjavik, Iceland, November 14, 2006
deCODE Announces Placement of $65 Million Of Convertible Notes

Reykjavik, Iceland, November 13, 2006
deCODE Announces Proposed Convertible Notes Offering

Reykjavik, Iceland, November 8, 2006
deCODE genetics Announces Third Quarter Financial Results

Reykjavik, Iceland, October 30, 2006
deCODE genetics Announces Webcast of Conference Call to Discuss Third Quarter Financial Results

Reykjavik, Iceland, October 26, 2006
deCODE genetics to Webcast Presentation at C.E. Unterberg Life Sciences Conference

Reykjavik, Iceland, October 23, 2006
deCODE Appoints Senior Vice President of Corporate Development

Reykjavik, Iceland, October 5, 2006
deCODE Suspends Phase III Trial of DG031 to Improve Tablet Manufacturing

Reykjavik, Iceland, September 26, 2006
deCODE Files Suit to Defend Intellectual Property

Reykjavik, Iceland, September 13, 2006
deCODE Announces Appointment of Peter Goodfellow to Board of Directors

Reykjavik, Iceland, August 31, 2006
deCODE genetics to Webcast Presentations at BioCentury, Thomas Weisel Investor Conferences

Reykjavik, Iceland, August 14, 2006
deCODE Initiates Phase I Clinical Program for DG051 for the Prevention of Heart Attack

Washington, August 10, 2006 - National Minority Health Month Foundation
Minority-Based Health Care Organizations Endorse Landmark Clinical Trial for the Prevention of Heart Attack

Reykjavik, Iceland, August 8, 2006
deCODE genetics Announces Second Quarter 2006 Financial Results

Reykjavik, Iceland, July 31, 2006
deCODE genetics Announces Webcast of Conference Call to Discuss Second Quarter Financial Results
Reykjavik, Iceland, July 18, 2006
deCODE Appoints Earl Collier to Board of Directors

Reykjavik, Iceland, July 14, 2006
deCODE to Raise $30 Million in Common Stock Offering

Reykjavik, Iceland, June 29, 2006
deCODE Submits IND on DG051 for the Prevention of Heart Attack

Reykjavik, Iceland, June 28, 2006
deCODE Announces Appointment of Birgit Norinder to Board of Directors

Reykjavik, Iceland, June 26, 2006
deCODE Provides Product Development Update
Reykjavik, Iceland, June 26, 2006
deCODE Announces Positive Results from Preliminary Phase II Clinical Trial of CEP-1347 in Asthma
Reykjavik, Iceland, June 23, 2006
deCODE genetics to Webcast Presentation at Jefferies Life Sciences Conference
Reykjavik, Iceland, June 22, 2006
deCODE Initiates Phase II Clinical Program for DG041 for Peripheral Artery Disease
Reykjavik, Iceland, June 21, 2006
deCODE genetics to Webcast Presentations at its Annual R&D Event
Reykjavik, Iceland, June 20, 2006
deCODE Study Links Gene Variant to Risk of Breast Cancer
Reykjavik, Iceland, June 07, 2006
deCODE genetics to Webcast Presentation at Pacific Growth Equities Life Sciences Growth Conference

Reykjavik, Iceland, May 30, 2006
deCODE Announces Changes in Leadership of Business Development

Reykjavik, Iceland, May 17, 2006
deCODE Initiates Phase III Trial for DG031 for the Prevention of Heart Attack
Pioneering use of human genetics to target the causative biology of the leading cause of death in the industrialized world
Reykjavik, Iceland, and San Diego, California, May 15, 2006
deCODE and Illumina Form Alliance to Develop and Commercialize DNA-based Diagnostics

Reykjavik, Iceland, May 7, 2006
deCODE Discovers Major Genetic Risk Factor for Prostate Cancer

Reykjavik, Iceland, May 3, 2006
deCODE Announces Special Protocol Assessment Agreement with the FDA for Phase III Clinical Trial of DG031

Reykjavik, Iceland, May 1, 2006
deCODE genetics Announces First Quarter 2006 Financial Results
Reykjavik, Iceland, April 28, 2006
deCODE genetics to Webcast Presentation at Morgan Stanley Global Healthcare Unplugged Conference
Reykjavik, Iceland, April 27, 2006
deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter Financial Results
Reykjavik, Iceland, March 27, 2006
deCODE genetics to Webcast Presentation at 13th Annual Future Leaders in the Biotech Industry Conference
Reykjavik, Iceland, March 6, 2006
deCODE genetics Announces Full-year 2005 Financial Results
Advancing the development of new drugs for heart attack, peripheral artery disease, asthma and pain; Executing on strategy to capture maximum value from focused investment in R&D
Reykjavik, Iceland, March 3, 2006
deCODE genetics to Webcast Presentation at Lehman Brothers Ninth Annual Global Healthcare Conference
Reykjavik, Iceland, February 27, 2006
deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2005 Financial Results
Reykjavik, Iceland, February 21, 2006
deCODE Successfully Completes Phase I Clinical Program for DG041 for the Treatment of Peripheral Artery Disease
Reykjavik, Iceland, February 10, 2006
deCODE genetics to Webcast Presentation at BIO CEO & Investor Conference
Reykjavik, Iceland, February 6, 2006
deCODE genetics Announces Webcast of Presentation at the Nasdaq U.S. Small Cap Conference
Reykjavik, Iceland, January 18, 2006
deCODE Expands Cancer Program through Acquisition of Icelandic Cancer Research Group
Reykjavik, Iceland, January 15, 2006
deCODE Discovers Major Genetic Risk Factor for Type 2 Diabetes
Most significant inherited component of T2D yet found; Discovery may enable development of diagnostics and drugs of major benefit to public health
Reykjavik, Iceland, January 4, 2006
deCODE genetics Announces Webcast of Presentation at the JP Morgan 24th Annual Healthcare Conference



www.decode.comSitemapContact deCODE geneticsSubscribe to the deCODE mailing listLegal Notice